Making India A $100-bn Biomanufacturing Hub By 2024
Express Pharma|February 16-29, 2020
Industry experts outline how Prime Minister Narendra Modi's dream of 'Make in India' for the biomanufacturing sector can be fulfilled in the stipulated time frame
Akanki Sharma
Making India A $100-bn Biomanufacturing Hub By 2024

As the year 2020 began, Prime minister Narendra Modi came up with good news for the biotechnology sector. Speaking at the inauguration of the 107th session of the Indian Science Congress at the University of Agricultural Sciences in Bengaluru last month, Modi said, “We aim to develop India as a world-class $100-billion biomanufacturing hubby 2024.”

“The growth story of India depends on its achievements in the science and technology sector. There is a need to revolutionize the landscape of Indian science, technology and innovation. My motto for the young scientists burgeoning in this country has been -innovate, patent, produce and prosper. These four steps will lead our country towards faster development. If we innovate, we will patent and that, in turn, will make our production smoother and when we take these products to the people of our country, they will prosper. Innovation for the people and by the people is the direction of our ‘New India’,” he added.

While the biotechnology sector is one of the key drivers for contributing to India's $5 trillion economy target by 2024, the Indian biotechnology sector is poised to grow exponentially over the next decade. Further, the country is among the top-12 destinations for biotechnology in the world, with approximately three per cent share in the global biotechnology industry.

The biotech sector can be broadly divided into five major segments — biopharma (which accounts for around 55 per cent of the revenue of the total sector), bio-agri (22 per cent of market share), services, bioindustrial and bioinformatics. According to Invest India, the National Investment Promotion and Facilitation Agency, the Indian biotechnology industry was valued at $51-billion in 2018 and is growing at almost 15 per cent year-on-year.

Potential that the biotechnology sector holds

Denne historien er fra February 16-29, 2020-utgaven av Express Pharma.

Start din 7-dagers gratis prøveperiode på Magzter GOLD for å få tilgang til tusenvis av utvalgte premiumhistorier og 9000+ magasiner og aviser.

Denne historien er fra February 16-29, 2020-utgaven av Express Pharma.

Start din 7-dagers gratis prøveperiode på Magzter GOLD for å få tilgang til tusenvis av utvalgte premiumhistorier og 9000+ magasiner og aviser.

FLERE HISTORIER FRA EXPRESS PHARMASe alt
MAKING SUSTAINABILITY SUSTAINABLE
Express Pharma

MAKING SUSTAINABILITY SUSTAINABLE

Driven by stringent regulations, rising investor expectations, consumer demand, and operational considerations, MSME pharma companies need to carefully balance their sustainability goals with financial viability

time-read
10+ mins  |
September 2024
New energy recovery system for tablet coaters
Express Pharma

New energy recovery system for tablet coaters

Upto 50 per cent less steam energy consumption

time-read
5 mins  |
September 2024
The future of pharma logistics: Trends, challenges, and opportunities
Express Pharma

The future of pharma logistics: Trends, challenges, and opportunities

Nikhil Agarwal, President, CJ Darcl Logistics explains that the future of pharma logistics is a thrilling frontier shaped by technological advancements, regulatory challenges, and the imperative of sustainability. As the industry transforms, logistics providers must embrace innovative solutions and adapt to shifting demands

time-read
3 mins  |
September 2024
Achieving Aatmanirbharta In APIs Are We On The Right Track?
Express Pharma

Achieving Aatmanirbharta In APIs Are We On The Right Track?

As India gears up to celebrate its 75th Independence Day, self reliance in APIs remains a key goal for the pharma sector. AatmaNirbharta will be crucial for the sector as it continues to protect the country from the existing and emerging health threats

time-read
9 mins  |
August 2021
Yokogawa launches OpreX Data Model Broker
Express Pharma

Yokogawa launches OpreX Data Model Broker

A plant data transformation platform, OpreX automatically verifies discrepancies and inconsistencies in data to improve efficiency in plant construction and operation

time-read
2 mins  |
August 2021
Understanding the nuances of generics injectables
Express Pharma

Understanding the nuances of generics injectables

At a webinar, explaining the West Pharma's AccelTRA Components Program, industry experts explained why the use of glass vials and stoppers as primary container closure systems (CCS) has become crucial

time-read
6 mins  |
August 2021
Trending in nutraceuticals: Science meets sustainability
Express Pharma

Trending in nutraceuticals: Science meets sustainability

Zeljko Pockaj, Vice President, Global Pharmaceutical Industry, mentions the key trends that are believed to drive innovations and formulations for nutraceuticals’ development around the globe

time-read
3 mins  |
August 2021
The growth of e-pharmacies in India
Express Pharma

The growth of e-pharmacies in India

Rahul Nath Choudhury, Research fellow, ICWA, explains what motivates people in the pharma industry to invest into e-pharmacies, along with various other growth factors associated with these

time-read
4 mins  |
August 2021
Xylitol and Maltitol: Low-calorie sugar alternatives
Express Pharma

Xylitol and Maltitol: Low-calorie sugar alternatives

Polyols like Xylitol and Maltitol offer important health benefits. Unlike general sugar-free sweeteners, these do not have any bitter-after taste

time-read
4 mins  |
August 2021
Single-use TC gaskets and their importance
Express Pharma

Single-use TC gaskets and their importance

Depending on the application, gaskets are manufactured by different types of Material of Construction (MOC) such as Silicone, EPDM, Viton (FKM), Nitrile, Neoprene, PTFE, etc.

time-read
2 mins  |
August 2021